Sixty-three postmenopausa/ women, who had an excessive fall/ of hair as predominant symptom in this phase of their life, felt in our study. All patients have done routine diagnostic test, hormonal dosage, and trichogram.
The patients have been randomized in three equa/ groups to which a different treatment had been administered:
1st group: Ethynilestradiol 0.02 mgldie from the 1st to the 25 th day of each month. A daily dose of 10 mg medroxyprogesterone acetale (MPA) was added tor the fast 10 days of estrogen administration.
2nd group: Transdermal es/radio/ 0.05 mg associated with medroxyprogesterone acetale (MPA) tor the fast 10 days of estrogen administration.
3rd group: Ethynilestradiol 0.02 mgldie from the 1st to the 25 th day of each month. A daily dose ot 12.5 mg cyproterone acetale was added far the tirsi 10 days of estrogen administration.
The hormonal assays and the trichogram were repeated after one year of treatment. SHBG values increase singnificantly (p<0.001) in patients belonging to the first and to the third group. On the contrary these values did not change in a statistically significant way in patients belonging to the second group. The per cent modifications of the hair diagrams were also significant in patients belonging to the first and third group.
The results obtained from this study seem to suggest thai the ethynil/estradiol rather than the antiandrogens was responsible of the benefical outcome in the treatment of androgenetic alopecia in postmenopausal women.
Privacy e Cookie Policy
Cookie Policy
Privacy Policy
Privacy Policy
Il gruppo
Copyright © 2024 Prof. Vittorio Unfer.